查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1795298

全球体内注射器市场

On-Body Injectors
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 177 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计到 2030 年全球体内注射器市场规模将达到 70 亿美元

全球体表注射器市场规模预计在2024年达到41亿美元，预计2024年至2030年期间的复合年增长率为9.5%，到2030年将达到70亿美元。本报告分析的细分市场之一－电子注射器，预计其复合年增长率将达到11.1%，到分析期结束时规模将达到47亿美元。机械注射器细分市场在分析期间的复合年增长率预计为6.7%。

美国市场规模估计为 11 亿美元，中国市场预期复合年增长率为 9.1%

美国人体注射器市场规模预估2024年达到11亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到11亿美元，在2024-2030年的分析期间内，复合年增长率为9.1%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为8.9%和7.8%。在欧洲，预计德国市场的复合年增长率约为7.4%。

全球体内注射器市场－主要趋势与驱动因素摘要

为什么体内注射器会彻底改变药物传递方式

体表注射器 (OBI) 是一种可穿戴式给药系统，旨在在可控的时间内内皮下注射大量生技药品或药物。这些装置通常佩戴在腹部或手臂上，方便患者在家中自行给药，减少对医院输液和频繁就诊的依赖。体表注射器尤其适用于需要定期给药的慢性疾病，例如癌症、自体免疫疾病和糖尿病。

以患者为中心、微创且便捷的给药解决方案的需求日益增长，推动了其应用。 OBI 能够最大限度地减少给药不适，且无需患者主动参与，从而提高治疗依从性。它们还能输送高黏度生技药品，而这些製剂无法使用传统的预填充式注射器或自动注射器快速注射。这种向可穿戴注射器的转变与远端医疗和居家护理的广泛趋势相吻合。

设备设计和技术的进步如何改善体内注射器？

技术创新正在透过改进人体工学、安全性和功能性来塑造下一代体表注射器。最新的体表注射器 (OBI) 配备预填充储药器、自动针头插入和回缩装置，以及用于引导患者的音讯或视觉指示器。一些设备甚至实现了数位连接，可将使用数据传输给医疗保健提供者，以实现远端监控和治疗管理。

微型组件、更强的皮肤黏合剂以及整合的压力感测器和微型帮浦使设备更加隐蔽，佩戴更舒适。药物输送现在可以控制在几分钟到几小时内完成，给药量可达5毫升或更大。与高黏度製剂的兼容性得到改善，也使得单株抗体、荷尔蒙和长效治疗药物（先前仅限于静脉注射）可以进行皮下给药。

哪些治疗和市场趋势推动了 OBI 使用的增加？

慢性病的增多和生物製药的核准，推动了对OBI等患者友善给药系统的需求。在肿瘤学领域，像Pegfilgrastim这样的药物在体内给药可以实现门诊病人治疗模式，并降低住院相关的感染风险。在类风湿性关节炎和克隆氏症自体免疫疾病中，OBI可以实现常规生物製药治疗，而无需承受注射带来的疲劳和奔波负担。

製药公司越来越多地将OBI纳入临床试验和商业化计划，共同开发药械组合产品。监管机构鼓励这种整合发展，并认识到设备在提高治疗依从性方面的作用。此外，付款人和医疗保健系统正在支援家庭管理，以降低住院和输液中心的成本。这些趋势正在将OBI的作用从利基生技药品扩展到更广泛的慢性病管理。

哪些因素推动了体内注射器市场的成长？

体内注射器市场的成长受到多种因素的推动。慢性病和文明病的增加推动了对长期药物输送解决方案的需求。生物製药（包括高浓度和高黏稠度药物）的进步推动了对穿戴式输送平台的需求。患者对自我给药和家庭治疗的偏好加速了 OBI 的采用，尤其是在肿瘤学、免疫学和内分泌学领域。设备设计、安全性和数位整合的技术改进正在推动监管部门的核准和市场渗透。此外，医疗成本压力和向价值型护理的转变正在鼓励製药和设备公司投资 OBI，以降低治疗复杂性、提高依从性并改善患者生活品质。这些因素支持了穿戴式註射器发展和全球市场的强劲势头。

部分

类型（电子注射器、机械注射器）；疾病（糖尿病、心血管疾病、神经系统疾病、免疫肿瘤疾病、其他疾病）；最终用户（医院/诊所最终用户、门诊手术中心最终用户、其他最终用户）

受访公司范例

  • AbbVie Inc.
  • Amgen Inc.
  • AptarGroup Inc.
  • BD（Becton, Dickinson & Co.）
  • Coherus BioSciences, Inc.
  • Debiotech SA
  • E3D Elcam Drug Delivery Devices
  • Enable Injections
  • Gerresheimer AG
  • Insulet Corporation
  • LTS Lohmann Therapie-Systeme AG
  • Medtronic plc
  • Nemera
  • Roche（Accu-Chek）
  • Sanofi
  • ScPharmaceuticals（ScPharma）
  • Sensile Medical AG
  • SteadyMed Therapeutics
  • Stevanato Group
  • West Pharmaceutical Services, Inc.
  • Ypsomed AG

人工智慧集成

全球产业分析师利用可操作的专家内容和人工智慧工具改变市场和竞争情报。

Global Industry Analysts 没有查询通用的 LLM 或特定产业的SLM，而是建立了一个来自世界各地专家的精选内容库，其中包括视频录像、博客、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地和进出口（成品和原始设备製造商）情况预测其竞争地位的变化。这种复杂而多面的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 其他地区

第四章 竞赛

简介目录
Product Code: MCP37566

Global On-Body Injectors Market to Reach US$7.0 Billion by 2030

The global market for On-Body Injectors estimated at US$4.1 Billion in the year 2024, is expected to reach US$7.0 Billion by 2030, growing at a CAGR of 9.5% over the analysis period 2024-2030. Electronic Injectors, one of the segments analyzed in the report, is expected to record a 11.1% CAGR and reach US$4.7 Billion by the end of the analysis period. Growth in the Mechanical Injectors segment is estimated at 6.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 9.1% CAGR

The On-Body Injectors market in the U.S. is estimated at US$1.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 9.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.9% and 7.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.4% CAGR.

Global On-Body Injectors Market - Key Trends & Drivers Summarized

Why Are On-Body Injectors Transforming Drug Delivery Practices?

On-body injectors (OBIs) are wearable drug delivery systems designed to administer large-volume biologics or medications subcutaneously over a controlled period. These devices are typically applied to the abdomen or arm and allow patients to self-administer treatments at home, reducing dependence on hospital-based infusions or frequent clinical visits. On-body injectors are particularly useful for chronic conditions that require regular dosing, such as cancer, autoimmune disorders, and diabetes.

Their adoption is rising due to growing demand for patient-centric, minimally invasive, and convenient drug delivery solutions. OBIs support better treatment adherence by allowing administration with minimal patient discomfort and without active engagement during delivery. They also enable delivery of high-viscosity biologics that cannot be injected rapidly with traditional prefilled syringes or autoinjectors. This shift toward wearable injectors aligns with broader trends in remote care and at-home therapeutics.

How Are Device Design and Technology Advancements Enhancing On-Body Injectors?

Technological innovation is shaping the next generation of on-body injectors through improved ergonomics, safety, and functionality. Modern OBIs feature prefilled drug reservoirs, automatic needle insertion and retraction mechanisms, and audible or visual indicators to guide patients through the process. Some devices offer digital connectivity, enabling transmission of usage data to healthcare providers for remote monitoring and treatment management.

Miniaturization of components, enhanced skin adhesives, and integration of pressure sensors and micro-pumps are making devices more discreet and comfortable to wear. Drug delivery can now be controlled over durations ranging from a few minutes to several hours, allowing administration of volumes up to 5 mL or more. Compatibility with high-viscosity formulations is also improving, enabling subcutaneous delivery of monoclonal antibodies, hormones, and long-acting therapeutics that were previously limited to intravenous routes.

What Therapeutic and Market Trends Are Expanding the Use of OBIs?

Growing prevalence of chronic diseases and biologic drug approvals is driving demand for patient-friendly delivery systems like OBIs. In oncology, on-body delivery of drugs such as pegfilgrastim is enabling outpatient care models and reducing infection risk from clinic visits. In autoimmune conditions such as rheumatoid arthritis and Crohn’s disease, OBIs allow regular biologic therapy without injection fatigue or travel burden.

Pharmaceutical companies are increasingly co-developing drug-device combination products, incorporating OBIs in clinical trials and commercialization plans. Regulatory bodies are encouraging such integrated development, recognizing the role of devices in improving therapy compliance. Additionally, payers and healthcare systems are supporting at-home administration to reduce hospitalization and infusion center costs. These trends are expanding the role of OBIs from niche biologics to broader chronic disease management.

What Factors Are Driving Growth in the On-Body Injectors Market?

Growth in the on-body injectors market is driven by several factors. Rising burden of chronic and lifestyle diseases is increasing demand for long-term drug delivery solutions. Advances in biologic formulations, including high-concentration and high-viscosity drugs, are driving need for wearable delivery platforms. Patient preference for self-administration and at-home treatment is accelerating adoption of OBIs, particularly in oncology, immunology, and endocrinology. Technological improvements in device design, safety, and digital integration are supporting regulatory approvals and market penetration. Additionally, healthcare cost pressures and the shift toward value-based care are encouraging pharmaceutical and device companies to invest in OBIs that reduce treatment complexity, improve adherence, and enhance patient quality of life. These factors collectively support strong momentum in wearable injector development and global market expansion.

SCOPE OF STUDY:

The report analyzes the On-Body Injectors market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Electronic Injectors, Mechanical Injectors); Disease (Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease, Other Diseases); End-Use (Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • AptarGroup Inc.
  • BD (Becton, Dickinson & Co.)
  • Coherus BioSciences, Inc.
  • Debiotech SA
  • E3D Elcam Drug Delivery Devices
  • Enable Injections
  • Gerresheimer AG
  • Insulet Corporation
  • LTS Lohmann Therapie-Systeme AG
  • Medtronic plc
  • Nemera
  • Roche (Accu-Chek)
  • Sanofi
  • ScPharmaceuticals (ScPharma)
  • Sensile Medical AG
  • SteadyMed Therapeutics
  • Stevanato Group
  • West Pharmaceutical Services, Inc.
  • Ypsomed AG

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • On-Body Injectors - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Chronic Diseases Propels Demand for Self-Administered, Long-Acting Drug Delivery Devices
    • Shift Toward Home-Based Care Expands Addressable Market for Wearable and On-Body Injection Systems
    • Growth in Biologics and Large-Molecule Therapies Strengthens Business Case for On-Body Delivery Platforms
    • Increased Focus on Patient Adherence and Convenience Drives Adoption of Hands-Free Injection Devices
    • Advancements in Microelectronics and Battery Technologies Enhance Reliability and Portability of On-Body Injectors
    • Regulatory Support for Connected Health Solutions Spurs Development of Smart On-Body Devices with Monitoring Capabilities
    • Expansion of Subcutaneous Drug Formulations Generates Opportunities for Alternative to In-Clinic Infusion Therapy
    • Integration of Wireless Connectivity and App-Based Interfaces Promotes Real-Time Dose Tracking and Alerts
    • Rising Healthcare Costs and Workforce Shortages Accelerate Use of Automated Injection Systems to Reduce Hospital Dependence
    • Increase in FDA Approvals and CE Marking of Wearable Injectors Boosts Commercial Availability and Market Access
    • Patient-Centric Design Trends Spur Innovation in Painless, Low-Profile On-Body Injection Devices
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World On-Body Injectors Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for On-Body Injectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for On-Body Injectors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Electronic Injectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Electronic Injectors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Mechanical Injectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Mechanical Injectors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diabetes Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Diabetes Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Cardiovascular Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Neurological Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Neurological Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Immuno-Oncological Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Immuno-Oncological Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • On-Body Injectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 24: USA Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • CANADA
    • TABLE 30: Canada Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • JAPAN
    • On-Body Injectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 36: Japan Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • CHINA
    • On-Body Injectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 42: China Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • EUROPE
    • On-Body Injectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 48: Europe Recent Past, Current & Future Analysis for On-Body Injectors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for On-Body Injectors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • FRANCE
    • On-Body Injectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 58: France Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • GERMANY
    • On-Body Injectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 64: Germany Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 70: Italy Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • UNITED KINGDOM
    • On-Body Injectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 76: UK Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • ASIA-PACIFIC
    • On-Body Injectors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for On-Body Injectors by Type - Electronic Injectors and Mechanical Injectors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World 6-Year Perspective for On-Body Injectors by Type - Percentage Breakdown of Value Sales for Electronic Injectors and Mechanical Injectors for the Years 2025 & 2030
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for On-Body Injectors by End-Use - Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of World 6-Year Perspective for On-Body Injectors by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2025 & 2030
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for On-Body Injectors by Disease - Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of World 6-Year Perspective for On-Body Injectors by Disease - Percentage Breakdown of Value Sales for Diabetes Disease, Cardiovascular Disease, Neurological Disease, Immuno-Oncological Disease and Other Diseases for the Years 2025 & 2030

IV. COMPETITION